CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...